ACTIVATED MACROPHAGE/MONOCYTE TGFB1-INDUCED UPREGULATION OF COLLAGEN SYNTHESIS
活化巨噬细胞/单核细胞 TGFB1 诱导胶原合成上调
基本信息
- 批准号:6235660
- 负责人:
- 金额:$ 10.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-07-01 至 1998-06-30
- 项目状态:已结题
- 来源:
- 关键词:antibody specificity autoantibody autoimmune disorder bone marrow transplantation collagen disease /disorder model fibroblasts fibrosis gene expression graft versus host disease histopathology immunoprecipitation in situ hybridization laboratory mouse link protein macrophage monocyte northern blottings phenotype protein biosynthesis scleroderma sclerosis skin transforming growth factors ultrasonography western blottings
项目摘要
Systemic sclerosis/scleroderma is a chronic autoimmune disease of unknown
etiology, characterized by the excessive deposition of collagen in
viscerae and skin, altered cell-mediated immunity, and the production of
autoantibodies. Existing murine models for scleroderma are limited in
their usefulness for study of the complex immunologic abnormalities, and
human disease is difficult to study because the early changes are subtle
and diagnosis is often delayed. Evidence from in vitro and in vivo work on
pulmonary lesions in human scleroderma suggest that TGFbeta1 produced by
infiltrating monocytes is a potent stimulus for collagen gene upregulation
by fibroblasts leading to fibrosis. A murine sclerodermatous graft-versus-
host disease (GVHD) model (C57BL/6J to LP/J) in which animals develop
GVHD, skin thickening and autoantibodies after bone marrow transplantation
across minor histocompatibility loci (H-2b) provides the ideal opportunity
to study these events in an intact organism. Control mice receiving the
reciprocal bone marrow transplantation LP/6 to C57BL/6J develop GVHD and
dermal mononuclear cell infiltrates, but do not develop the skin
thickening. Aim I of this proposal will characterize fully the
sclerodermatous GVHD mice and confirm their usefulness as a model for
human scleroderma. Disease progression will be correlated with histologic,
biochemical and immunologic parameters by measuring dermal thickness using
ultrasonography and physical measurements of intact skin and histologic
sections, assaying autoantibody production by antinuclear antibody tests,
immunophenotyping of the dermal mononuclear infIltrating cells, and
quantifying dermal collagen gene expression by northern blot analysis of
total RNA prepared from dermis at time points after transplantation in
sclerodermatous and control animals. Aim II tests the central role of
TGFbeta1-producing monocytes in causing collagen gene upregulation leading
to skin fibrosis. Immunophenotyping and in situ hybridization using
TGFbeta1 and pro-alpha(I)collagen probes to demonstrate co-localization of
TGFbeta1-producing monocytes and collagen-producing fibroblasts in early
skin lesions is the goal of this proposed work. Finally, the model
provides a system in which variables can be manipulated to test the
hypothesis that monocyte TGFbeta1 production is critical to initiation and
progression of fibrosis, a logical extension of the work proposed here.
Developing the murine model, confirming its validity for scleroderma, and
identifying major early immunologic events in scleroderma will provide a
means to test innovative immunotherapies in vivo.
系统性硬化症/硬皮病是一种慢性自身免疫性疾病,
病因学,其特征在于胶原蛋白的过度沉积,
内脏和皮肤,改变细胞介导的免疫力,和生产
自身抗体现有的硬皮病小鼠模型在以下方面受到限制:
它们对研究复杂的免疫异常的有用性,以及
人类疾病很难研究,因为早期的变化是微妙的,
并且诊断常常被延迟。来自体外和体内研究的证据
人类硬皮病的肺部病变表明,
浸润的单核细胞是胶原基因上调的有力刺激物
导致纤维化一种小鼠硬皮病移植物抗
宿主疾病(GVHD)模型(C57 BL/6 J至LP/J),其中动物发展
骨髓移植后GVHD、皮肤增厚和自身抗体
跨次要组织相容性位点(H-2b)提供了理想的机会
在一个完整的有机体中研究这些事件。对照小鼠接受
LP/6至C57 BL/6 J的相互骨髓移植发生GVHD,
真皮单核细胞浸润,但不发育皮肤
增厚本提案的目标一将充分描述
硬皮病GVHD小鼠,并确认其作为模型的有用性,
人类硬皮病疾病进展将与组织学,
通过测量皮肤厚度的生化和免疫参数,
完整皮肤和组织学的超声和物理测量
切片,通过抗核抗体试验测定自身抗体的产生,
真皮单核细胞浸润细胞的免疫表型,和
通过北方印迹分析定量真皮胶原基因表达,
在移植后的时间点从真皮中制备的总RNA,
硬皮病动物和对照动物。目标二检验了
产生TGF β 1的单核细胞引起胶原基因上调,
皮肤纤维化免疫表型和原位杂交,
TGF β 1和pro-alpha(I)胶原蛋白探针,以证明TGF β 1和pro-alpha(I)胶原蛋白的共定位。
早期乳腺癌中产生TGF β 1的单核细胞和产生胶原的成纤维细胞
皮肤损伤是本建议工作的目标。最后对模型
提供了一个系统,在该系统中,可以操纵变量来测试
假设单核细胞TGF β 1的产生对于启动和
纤维化的进展,这里提出的工作的逻辑延伸。
建立小鼠模型,确认其对硬皮病的有效性,
确定硬皮病的主要早期免疫学事件将提供一个
在体内测试创新的免疫疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANITA C GILLIAM其他文献
ANITA C GILLIAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANITA C GILLIAM', 18)}}的其他基金
Immune mechanisms that lead to irreversible scleroderma.
导致不可逆硬皮病的免疫机制。
- 批准号:
7072675 - 财政年份:2004
- 资助金额:
$ 10.85万 - 项目类别:
Immune mechanisms that lead to irreversible scleroderma.
导致不可逆硬皮病的免疫机制。
- 批准号:
6848873 - 财政年份:2004
- 资助金额:
$ 10.85万 - 项目类别:
Immune mechanisms that lead to irreversible scleroderma
导致不可逆硬皮病的免疫机制
- 批准号:
6731601 - 财政年份:2004
- 资助金额:
$ 10.85万 - 项目类别:
Immune mechanisms that lead to irreversible scleroderma
导致不可逆硬皮病的免疫机制
- 批准号:
7221297 - 财政年份:2004
- 资助金额:
$ 10.85万 - 项目类别:
Chemokine antagonists in a murine model for scleroderma
硬皮病小鼠模型中的趋化因子拮抗剂
- 批准号:
6512134 - 财政年份:2001
- 资助金额:
$ 10.85万 - 项目类别:
Chemokine antagonists in a murine model for scleroderma
硬皮病小鼠模型中的趋化因子拮抗剂
- 批准号:
6405655 - 财政年份:2001
- 资助金额:
$ 10.85万 - 项目类别:
Chemokine antagonists in a murine model for scleroderma
硬皮病小鼠模型中的趋化因子拮抗剂
- 批准号:
6606177 - 财政年份:2001
- 资助金额:
$ 10.85万 - 项目类别:
INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS
抑制单核细胞 TGFB1 诱导的皮肤纤维化
- 批准号:
6045340 - 财政年份:2000
- 资助金额:
$ 10.85万 - 项目类别:
INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS
抑制单核细胞 TGFB1 诱导的皮肤纤维化
- 批准号:
6512005 - 财政年份:2000
- 资助金额:
$ 10.85万 - 项目类别:
相似海外基金
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
桥粒芯糖蛋白 3 嵌合自身抗体受体 T 细胞 (DSG3-CAART) 对粘膜寻常型天疱疮的免疫调节作用
- 批准号:
10679911 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
- 批准号:
10639707 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Analysis of abnormal post-translational modifications that promote autoantibody production using high-precision mass spectrometry
使用高精度质谱分析促进自身抗体产生的异常翻译后修饰
- 批准号:
23K07915 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical application based on the molecular mechanism of autoantibody production in autoimmunity
基于自身抗体产生的分子机制在自身免疫中的临床应用
- 批准号:
23K18361 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Dynamic prediction of type 1 diabetes risk and autoantibody status by a joint model of longitudinal and multistate models
通过纵向和多状态模型的联合模型动态预测1型糖尿病风险和自身抗体状态
- 批准号:
10630731 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Novel therapeutic strategies targeting autoantibody-producing RP105-negative B cells by t-SNE method
通过 t-SNE 方法针对产生自身抗体的 RP105 阴性 B 细胞的新治疗策略
- 批准号:
23K07910 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Extracellular vesicle and autoantibody production
细胞外囊泡和自身抗体的产生
- 批准号:
23K15265 - 财政年份:2023
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of mechanism of autoantibody production in pemphigus in conjunction with information from single cell analysis
结合单细胞分析信息阐明天疱疮自身抗体产生的机制
- 批准号:
22K08416 - 财政年份:2022
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Influence of HTLV-1 for autoantibody production system and Th subset
HTLV-1对自身抗体产生系统和Th亚群的影响
- 批准号:
22K08552 - 财政年份:2022
- 资助金额:
$ 10.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multi-Platform Homogeneous Multiplexed Autoantibody Assay Based on Liquid Micropiston-Enhanced Time-Resolved Forster Resonance Energy Transfer
基于液体微活塞增强时间分辨福斯特共振能量转移的多平台同质多重自身抗体测定
- 批准号:
10576777 - 财政年份:2022
- 资助金额:
$ 10.85万 - 项目类别: